Veridien is developing new patentable products in concert with Mycosol, a company in which Veridien has invested and has the right to acquire majority ownership interest. Mycosol is a development-stage chemical and pharmaceutical company based in the Research Triangle Park area of North Carolina. The Company is developing a proprietary, low cost platform technology with the objective being to safely and effectively treat and prevent microbial-induced and microbial-exacerbated problems. Mycosol's proprietary multi-active compound has demonstrated potent anti-mold, anti-fungal, anti-bacterial, anti-inflammatory, and anti-allergic properties. Using this 'core technology' platform, a library of over 1,500 known analogs and 6 patents pending, Mycosol believes that a broad portfolio of products can be developed for many medical, industrial, veterinary and agricultural applications. Mycosol is also developing its core technology for use as safe and effective biological staining reagents in academic, biotechnology and pharmaceutical research laboratories.